Recombinant LINGO1 (Opicinumab Biosimilar) antibody
Quick Overview for Recombinant LINGO1 (Opicinumab Biosimilar) antibody (ABIN7676043)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
-
-
Expression System
- CHO Cells
-
Purpose
- Anti-LINGO1 Reference Antibody (opicinumab)
-
Sequence
- EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYEMKWVRQA PGKGLEWVSV IGPSGGFTFY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCATEG DNDAFDIWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNSA YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG,DIQMTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPMYTFG QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
-
Characteristics
- Anti-LINGO1 Reference Antibody (opicinumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Purity
- >95 %
-
Isotype
- IgG1
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Comment
-
Therapeutic Agents by Target and Mechanism: LINGO1 inhibitors, cell differentiation stimulus
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Storage
- 4 °C,-80 °C
-
Storage Comment
- +4°C,-80°C
-
-
- LINGO1 (Opicinumab Biosimilar)
-
Target Type
- Biosimilar
-
Molecular Weight
- 145.5 kDa
-
UniProt
- Q96FE5
Target
-